On medicines
With inflation surprising on the upside
As of 16 June
Innovative manufacturers give in to state pressure
Márton Nagy remains cryptic
Cross-hairs on non-subsidised medicines
By HSBC
Partners sign binding term sheet for joint development
New board member also elected at the General Meeting
Trump's tariffs could hit the Hungarian pharmaceutical company too
Drugs maker expects significant growth, especially in the women's healthcare and biotech segments
Portfolio expanding
Interview with Gábor Orbán
FDA accepts license application for review
Márton Nagy says the pharmaceutical sector could be one of the drivers of economic recovery
Third-quarter flash report came in
Analyst consensus available
Gynaecological product gets green light, milestone payment coming
Vrylar, jointly developed with US partner AbbVie, is the subject of the positive news
Some fear it could set back the development of treatments for rare diseases